netFormulary
 Report : Medicines with links to NICE 29/05/2020 15:32:44

[Back]

Report looks at the links table and pulls back all the items in the formulary where there is a link with 'nice.org' in the URL

You can sort this table Medicines Link Name or Link URL by clicking on the title

Selecting the Medicine name will take you to the entry in the formulary, Selecting the Link name will follow the link

 
Medicines/Item Section Status Link Name / Link URL
Abatacept 10.01.03 Restricted Use NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
Abatacept 10.01.03 Restricted Use NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Abemaciclib 08.01.05 Formulary NICE TA563:Abemaciclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
Abemaciclib 08.01.05 Formulary NICE TA579: Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy
Abiraterone 08.03.04.02 Restricted Use NICE TAG 259: Abiraterone for castration resistant prostate cancer
Abiraterone 08.03.04.02 Restricted Use NICE TA387:Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated
Adalimumab 13.05.03 Restricted Use NICE TA455:Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
Adalimumab 13.05.03 Restricted Use NICE TA392: Adalimumab for treating moderate to severe hidradenitis suppurativa
Adalimumab 01.05.03 Restricted Use NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis
Adalimumab 01.05.03 Restricted Use NICE TA187: Crohn’s disease - infliximab and adalimumab
Adalimumab 10.01.03 Restricted Use NICE TA199: Psoriatic arthritis
Adalimumab 10.01.03 Restricted Use NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
Adalimumab 10.01.03 Restricted Use NICE TA195: Rheumatoid arthritis - after failure of a TNF inhibitor
Adalimumab 10.01.03 Restricted Use NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Adalimumab 10.01.03 Restricted Use NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Adalimumab 11.04.02 Restricted Use NICE TA460: Adalimumab and dexamethasone for treating non-infectious uveitis
Adefovir Dipivoxil 05.03.03.01 Restricted Use NICE TA96: Hep B - adefovir dipivoxil and pegylated interferon alpha-2a
Adefovir Dipivoxil 05.03.03.01 Restricted Use NICE CG165: Hepatitis B (chronic) - incorporates TA96
Adrenaline / epinephrine 03.04.03 Formulary NICE 134: Anaphylaxis: Assessment and referral after emergency treatment
Afatinib 08.01.05 Restricted Use NICE TA310: Afatinib for non-small-cell lung cancer
Aflibercept 08.01.05 Restricted Use Visual impairment due to mycopic choroidal neovascularisation: afibercept
Aflibercept 08.01.05 Restricted Use NICE TA307: Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy
Aflibercept 11.08.02 Restricted Use NICE TA409:Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion
Aflibercept 11.08.02 Restricted Use NICE TA486:Aflibercept for treating choroidal neovascularisation
Alectinib 08.01.05 Restricted Use NICE TA536: Alectinib for untreated ALK-positive advanced non-small-cell lung cancer
Alemtuzumab 08.02.03 Restricted Use NICE TA312: Alemtuzumab for relapsing‑remitting multiple sclerosis
Alirocumab 02.12 Restricted Use NICE TA393: Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
Alteplase 02.10.02 Restricted Use NICE TA264: Ischaemic stroke (acute) - alteplase
Amoxicillin 05.01.01.03 Formulary COVID19: NICE (NG165) - managing suspected or confirmed pneumonia in the community
Anti-D (Rh0) Immunoglobulin 14.05.03 Formulary NICE TAG156: Anti-D in pregnant women
Apixaban 02.08.02 Formulary NICE TA275: Apixaban for AF
Apremilast 13.05.03 Restricted Use NICE TA 419: Apremilast for treating moderate to severe plaque psoriasis
Apremilast 13.05.03 Restricted Use NICE TA433: Apremilast for treating active psoriatic arthritis
Aripiprazole 04.02.01 Formulary Aripiprazole for the treatment of schizophrenia in people aged 15 -17 years (NICE TA 213)
Aripiprazole 04.02.01 Formulary Bipolar disorder (children) - aripiprazole (NICE TA292)
Arsenic Trioxide 08.01.05 Restricted Use NICE TA526: treatment for acute promyelocytic leukaemia
Asfotase alfa 09.08.01 Non Formulary NICE HST6: Asfotase alfa for treating paediatric-onset hypophosphatasia
Ataluren 10.02 Restricted Use HST3 - Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene
Atezolizumab 08.01.05 Restricted Use NICE TA520: Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy
Atezolizumab 08.01.05 Restricted Use NICE TA525: Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy.
Atezolizumab 08.01.05 Restricted Use NICE TA492: Atezolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable
Atezolizumab 08.01.05 Restricted Use NICE TA584:Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancer
Avelumab 08.02.03 Restricted Use NICE TA517: Avelumab for treating metastaic Merkel cell carcinoma
Axitinib 08.01.05 Restricted Use NICE TA333: Axitinib for advanced renal cell carcinoma
Azacitidine 08.01.03 Restricted Use NICE TA218: azacitidine for myelodysplastic syndromes
Azacitidine 08.01.03 Restricted Use NICE TA399: Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts
Azithromycin 05.01.05 Restricted Use NICE evidence summary: Long-term azithromycin for CF
Azithromycin 05.01.05 Restricted Use NICE evidence summary: Long-term azithromycin for non-CF bronchiectasis
Baricitinib 10.01.03 Restricted Use NICE TA466:Baricitinib for moderate to severe rheumatoid arthritis
Basiliximab 08.02.02 Formulary NICE TA482: Immunosuppressive therapy for kidney transplant in children and young people
Basiliximab 08.02.02 Formulary NICE TA481: Immunosuppressive therapy for kidney transplant in adults
Belimumab 10.01 Restricted Use NICE TA397: Belimumab for treating active autoantibody-positive systemic lupus erythematosus
Bendamustine 08.01.01 Restricted Use NICE TA 216: Bendamustine for CLL
Bevacizumab 08.01.05 Restricted Use NICE TA263: Breast cancer with capecitabine
Bevacizumab 08.01.05 Restricted Use NICE TA214: Breast Cancer with taxane
Bevacizumab 08.01.05 Restricted Use NICE TA285: Ovarian, fallopian tube and primary peritoneal cancer (recurrent advanced, platinum-sensitive or partially platinum-sensitive) - bevacizumab
Bevacizumab 08.01.05 Restricted Use NICE Evidence summary: Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer
Bivalirudin 02.08.01 Formulary NICE CG 94:Unstable angina and NSTEMI
Bivalirudin 02.08.01 Formulary NICE TAG 230 : Bivalirudin for the treatment of STEMI, 2011
Blinatumomab 08.02 Restricted Use NICE TA450:Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia
Blinatumomab 08.02 Restricted Use NICE TA589: Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity
Boceprevir 05.03.03.02 Non Formulary NICE TA253: hepatitis
Bortezomib 08.01.05 Formulary NICE TAG370: Bortezomib for previously untreated mantle cell lymphoma
Bortezomib 08.01.05 Formulary NICE TAG129: Multiple myeloma - bortezomib
Bortezomib 08.01.05 Formulary NICE TAG228: 1st line treatment of multiple myeloma
Bortezomib 08.01.05 Formulary NICE TAG311: Bortezomib for induction therapy in multiple myeloma
Bosutinib 08.01.05 Restricted Use NICE TA401: Bosutinib for previously treated chronic myeloid leukaemia
Botulinum Toxin Type A 04.09.03 Restricted Use NICE TA605: Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea
Brentuximab vedotin 08.01.05 Restricted Use NICE TA524: for treating CD30-positive Hodgkin lymphoma
Brentuximab vedotin 08.01.05 Restricted Use NICE TA478: Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma
Brexpiprazole 04.02.01 Non Formulary Bipolar disorder (children) - aripiprazole (NICE TA292)
Brexpiprazole 04.02.01 Non Formulary Aripiprazole for the treatment of schizophrenia in people aged 15 -17 years (NICE TA 213)
Brigatinib 08.01.05 Restricted Use NICE TA571: Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib
Budesonide 01.05.02 Formulary NICE: Evidence Summary (ESNM58)
Burosumab 06.06.02 Restricted Use HST8: Burosumab for treating X-linked hypophosphataemia in children and young people
Cabazitaxel 08.01.05 Restricted Use NICE TA391: Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel
Cabozantinib 08.01.05 Restricted Use NICE TA542: Cabozantinib for untreated advanced renal cell carcinoma
Cabozantinib 08.01.05 Restricted Use NICE TA463:Cabozantinib for previously treated advanced renal cell carcinoma
Cabozantinib 08.01.05 Restricted Use NICE TA516: Cabozantinib for treating medullary thyroid cancer
Canagliflozin 06.01.02.03 Formulary NICE TA315: Canagliflozin for type 2 diabetes
Canagliflozin 06.01.02.03 Formulary NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
Cangrelor 02.09 Non Formulary NICE advice [ESNM64]
Cangrelor 02.09 Non Formulary NICE TA351: Reducing Artherothrombotic Events
Cannabidiol (CBD) 04.08.01 Restricted Use NICE TA615: Cannabidiol with clobazam for treating seizures associated with Lennox–Gastaut syndrome
Cannabidiol (CBD) 04.08.01 Restricted Use NICE TA614: Cannabidiol with clobazam for treating seizures associated with Dravet syndrome
Capecitabine 08.01.03 Formulary NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin
Capecitabine 08.01.03 Formulary NICE TA61: Colorectal cancer - capecitabine and tegafur uracil
Capecitabine 08.01.03 Formulary NICE TA191: Gastric cancer (advanced) - capecitabine
Carbamazepine 04.02 Non Formulary NICE evidence summary: carbamazepine for behavioural disturbances in dementia
Carfilzomib 08.01.05 Restricted Use NICE TA457:Carfilzomib for previously treated multiple myeloma
Carmustine 08.01.01 Formulary NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide
Carmustine 08.01.01 Restricted Use NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide
Ceftolozane & tazobactam 05.01.02 Restricted Use NICE 2016: Evidence summary of new medicines: intra-abdominal
Ceftolozane & tazobactam 05.01.02 Restricted Use NICE 2016: Evidence summary of new medicines: UTI
Ceritinib 08.01.05 Restricted Use NICE TA500: Ceritinib for untreated ALK-positive non-small-cell lung cancer
Ceritinib 08.01.05 Restricted Use NICE TA395: Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer
Certolizumab Pegol 10.01.03 Restricted Use NICE TA574: Certolizumab pegol for treating moderate to severe plaque psoriasis
Certolizumab Pegol 10.01.03 Restricted Use NICE TA445:Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs
Certolizumab Pegol 10.01.03 Restricted Use NICE TA415: Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor
Certolizumab Pegol 10.01.03 Restricted Use NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Certolizumab Pegol 10.01.03 Restricted Use NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Cetirizine 03.04.01 Formulary NICE advice [ESUOM31]: Chronic urticaria: off-label doses of cetirizine
Cetuximab 08.01.05 Formulary NICE TA473: Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck
Cetuximab 08.01.05 Formulary NICE TA145: Head and neck cancer - cetuximab
Cetuximab 08.01.05 Formulary NICE TA439: Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
Ciclosporin 11.99.99.99 Restricted Use NICE TA369 - Ciclosporin for treating eye disease that has not improved despite treatment with artificial tears
Cinacalcet 09.05.01.02 Restricted Use NICE TA117: Hyperparathyroidism - cinacalcet
Cladribine 08.01.03 Formulary NICE TA616: Cladribine tablets for treating relapsing–remitting multiple sclerosis
Clonidine 02.05.02 Formulary NICE Evidence Summary: Clonidine for ADHD in children and young people
Clopidogrel 02.09 Formulary NICE Evidence summary: Clopidogrel for transient ischaemic attack
Cobimetinib 08.02.04 Non Formulary NICE TA414:Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma
Codeine 04.07.02 Formulary COVID19: NICE (NG163) Managing symptoms (incl EOL) in the community
Colesevelam 02.12 Formulary NICE Evidence Summary: Colesevelam for bile acid malabsorption
Colistimethate for nebulisation 05.01.07 Formulary NICE ESUOM25: Non-cystic fibrosis bronchiectasis: colistimethate sodium
Colistimethate inhaler 05.01.07 Restricted Use NICE: Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin (TA276)
Collagenase 10.03.01 Non Formulary NICE TA459:Collagenase clostridium histolyticum for Dupuytren’s contracture
Crizotinib 08.01.05 Restricted Use NICE TA529: Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer
Crizotinib 08.01.05 Restricted Use NICE TA406: Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
Crizotinib 08.01.05 Restricted Use NICE TA422: Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
Dabigatran 02.08.02 Formulary NICE TA249: Dabigatran for Stroke prevention in AF
Dabrafenib 08.01.05 Restricted Use NICE TA321:Dabrafenib for BRAF V600 +ve melanoma
Dabrafenib 08.01.05 Restricted Use NICE TA544: Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma
Dabrafenib 08.01.05 Restricted Use NICE TA396:Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
Daclatasvir 05.03.03.02 Non Formulary NICE TA364: Daclatasvir for treating chronic hepatitis C
Dapagliflozin 06.01.02.03 Formulary NICE TA597: Dapagliflozin with insulin for treating T1D
Dapagliflozin 06.01.02.03 Formulary NICE TA418: Dapagliflozin in triple therapy for treating type 2 diabetes
Dapagliflozin 06.01.02.03 Formulary NICE TA288: Dapagliflozin in combination therapy for treating T2D
Dapagliflozin 06.01.02.03 Formulary NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating T2D
Daratumumab 08.01.05 Restricted Use NICE TA510: Daratumumab monotherapy for treating relapsed and refractory multiple myeloma
Daratumumab 08.01.05 Restricted Use NICE TA573: Daratumumab with bortezomib and dexamethasone for previously treated multiple myeloma
Darbepoetin Alfa 09.01.03 Restricted Use NICE TA323: Erythropoiesis‑stimulating agents during chemotherapy
Darbepoetin Alfa 09.01.03 Restricted Use NICE NG8: Anaemia in chronic kidney disease
Dasabuvir 05.03.03.02 Restricted Use NICE TAG365: Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C
Dasatinib 08.01.05 Restricted Use NICE TA425:Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Dasatinib 08.01.05 Restricted Use NICE TA426:Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
Dasatinib 08.01.05 Restricted Use NICE TA426:Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
Debrisoft A5.07 Restricted Use NICE MTG17: Debrisoft for acute and chronic wounds
Decitabine 08.01.03 Non Formulary NICE: Leukaemia (acute myeloid ) - decitabine (terminated appraisal) (TA270)
Degarelix 08.03.04.02 Restricted Use NICE TA404:Degarelix for treating advanced hormone-dependent prostate cancer
Denosumab 06.06.02 Restricted Use NICE TA204: Osteoporotic fractures - denosumab
Denosumab 06.06.02 Restricted Use NICE: Bone metastases from solid tumours - denosumab: guidance (TA265 )
Dexamethasone intravitreal implant 11.04.01 Restricted Use NICE TA460: Adalimumab and dexamethasone for treating non-infectious uveitis
Dexamethasone intravitreal implant 11.04.01 Restricted Use NICE TA349: Diabetic Macular Oedema
Diltiazem 2% Cream/Ointment 01.07.04 Restricted Use NICE evidence summary
Dimethyl fumarate 08.02.04 Restricted Use NICE TA320: Dimethyl fumarate for multiple sclerosis
Dimethyl fumarate 08.02.04 Restricted Use NICE TA475: Dimethyl fumarate for treating moderate to severe plaque psoriasis
Dimethyl Fumarate 13.05.02 Restricted Use NICE TA475: Dimethyl fumarate for plaque psoriasis
DIMETHYL SULPHOXIDE Bladder Instillation 50% 07.04.04 Restricted Use NICE Unlicensed Medicine Summary 26: Dimethyl Sulfoxide Bladder Instillation
Dinutuximab beta 08.02.04 Restricted Use NICE TA538: Dinutuximab beta for treating neuroblastoma
Docetaxel 08.01.05 Formulary NICE TA101: Prostate cancer (hormone-refractory) - docetaxel
Docetaxel 08.01.05 Formulary NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer
Domperidone 04.06 Formulary NICE: Enteral feeds in children and young people: domperidone
Doxorubicin 08.01.02 Formulary NICE TA465: Olaratumab in combination with doxorubicin for treating advanced soft tissue sarcoma
Doxorubicin 08.01.02 Restricted Use NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Doxycycline 05.01.03 Formulary COVID19: NICE (NG165) - managing suspected or confirmed pneumonia in the community
Dronedarone 02.03.02 Formulary NICE TA197: Atrial fibrillation - dronedarone
Dulaglutide 06.01.02.03 Formulary NICE: Evidence Summary (ESNM59)
Dupilumab 13.05.03 Restricted Use NICE TA534: Dupilumab for treating moderate to severe atopic dermatitis
Durvalumab 08.01 Restricted Use NICE TA578: Durvalumab for treating locally advanced unresectable non-small-cell lung cancer
Eculizumab 09.01.03 Restricted Use NICE HST1: Eculizumab for atypical haemolytic uraemic syndrome
Eculizumab 09.01.03 Restricted Use NICE evidence summary: eculizumab for prevention of C3 glomerulopathy post-transplant
Edoxaban 02.08.02 Formulary NICE TA355:Edoxaban for preventing stroke/systemic embolism in non‑valvular AF
Eliglustat 09.08.01 Non Formulary NICE HST5- Eliglustat for treating type 1 Gaucher disease
Elosulfase alfa 09.08.01 Non Formulary NICE HST2: Elosulfase alfa for treating mucopolysaccharidosis type IVa
Eltrombopag 09.01.04 Restricted Use NICE TAG 293: Eltrombopag for treating chronic ITP
Empagliflozin 06.01.02.03 Formulary NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating T2D
Empagliflozin 06.01.02.03 Formulary NICE TA336: Empagliflozin for type 2 diabetes
Encorafenib 08.01.05 Formulary NICE TA562: Encorafenib with binimetinib for unresectable or metastatic BRAF V600 mutation-positive melanoma
Entecavir 05.03.03.01 Restricted Use NICE CG165: Hepatitis B (incorporates TA153)
Entecavir 05.03.03.01 Restricted Use NICE TA153: Hepatitis B (chronic) - entecavir
Enzalutamide 08.03.04.02 Restricted Use NICE TA316: Enzalutamide for prostate cancer
Enzalutamide 08.03.04.02 Restricted Use NICE TA377: Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated
EpiFix® A5.04 Non Formulary NICE EpiFix for Chronic Wounds
Eplerenone 02.02.03 Restricted Use NICE NG106: Chronic heart failure
Epoetin alfa 09.01.03 Restricted Use NICE TA323: Erythropoiesis‑stimulating agents during chemotherapy
Epoetin alfa 09.01.03 Restricted Use NICE NG8: Anaemia in chronic kidney disease
Epoetin beta 09.01.03 Restricted Use NICE NG8: Anaemia in chronic kidney disease
Epoetin beta 09.01.03 Restricted Use NICE TA323: Erythropoiesis‑stimulating agents during chemotherapy
Eribulin 08.01.05 Restricted Use NICE TA423: Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens
Eribulin 08.01.05 Restricted Use NICE TA515: Eribulin for treating locally advanced or metastatic breast cancer after 1 chemotherapy regimen
Erlotinib 08.01.05 Restricted Use NICE TA258: Lung cancer (non-small-cell) 1st line- erlotinib
Erlotinib 08.01.05 Restricted Use NICE TA227: Lung cancer (non-small-cell) maintenance - erlotinib
Erlotinib 08.01.05 Restricted Use NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
Ertugliflozin 06.01.02.03 Formulary NICE TA572: Ertugliflozin as monotherapy or with metformin for treating T2D
Ertugliflozin 06.01.02.03 Formulary NICE TA583: Ertugliflozin with metformin and a DPP4i for treating T2D
Erythromycin 05.01.05 Formulary NICE Evidence summary: Erythromycin for gastroparesis in adults
Etanercept 10.01.03 Restricted Use NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Etanercept 10.01.03 Restricted Use NICE TA199: Psoriatic arthritis
Etanercept 10.01.03 Restricted Use NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Etanercept 10.01.03 Restricted Use NICE TA195: Rheumatoid arthritis after the failure of a TNF inhibitor
Etanercept 10.01.03 Restricted Use NICE TA35: Adult psoriasis
Etanercept 10.01.03 Restricted Use NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for JIA
Etanercept 13.05.03 Formulary NICE TA455:Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
Etanercept 13.05.03 Formulary NICE TA103: Psoriasis - efalizumab and etanercept
Etanercept 10.01.03 Restricted Use NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Etanercept 10.01.03 Restricted Use NICE TA199: Psoriatic arthritis
Etanercept 10.01.03 Restricted Use NICE TA195: rheumatoid arthritis after the failure of a TNF inhibitor
Etanercept 10.01.03 Restricted Use NICE TA35: Adult psoriasis
Etanercept 10.01.03 Restricted Use NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Etanercept 10.01.03 Restricted Use NICE TA35: Adult psoriasis
Etanercept 10.01.03 Restricted Use NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Etanercept 10.01.03 Restricted Use NICE TA195: rheumatoid arthritis after the failure of a TNF inhibitor
Etanercept 10.01.03 Restricted Use NICE TA199: Psoriatic arthritis
Etanercept 10.01.03 Restricted Use NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Etelcalcetide 09.05.01.02 Restricted Use NICE TA448: Etelcalcetide for secondary hyperparathyroidism
Everolimus 08.02.02 Non Formulary NICE TA348: Preventing Rejection in Liver Transplant
Everolimus 08.01.05 Restricted Use NICE TA449:Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
Everolimus 08.01.05 Restricted Use NICE TA421:Everolimus with exemestane in advanced breast cancer after endocrine therapy
Everolimus 08.01.05 Restricted Use NICE TA432:Everolimus for advanced renal cell carcinoma after previous treatment
Everolimus 08.01.05 Restricted Use NICE TA348: Preventing Rejection in Liver Transplant
Evolocumab 02.12 Restricted Use NICE TA394: Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
Exenatide prolonged release 06.01.02.03 Formulary NICE TAG 248- MR exenatide
Ezetimibe 02.12 Formulary NICE TA385: Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia
Febuxostat 10.01.04 Restricted Use NICE TA164: Hyperuricaemia - febuxostat
Fentanyl 04.07.02 Restricted Use Moderate to severe acute post-operative pain: fentanyl transdermal patch
Filgrastim 09.01.06 Formulary NICE KTT15: Biosimilar medicines
Finasteride 06.04.02 Restricted Use NICE CG97 Lower urinary tract symptoms in men
Fingolimod 08.02.04 Restricted Use NICE TA254: Fingolimod for highly active relapsing remitting multiple sclerosis
Fludarabine Phosphate 08.01.03 Formulary NICE TA119: Leukaemia (lymphocytic) - fludarabine
Fludarabine Phosphate 08.01.03 Formulary NICE TA29: Leukaemia (lymphocytic) - fludarabine
Fludrocortisone 06.03.01 Formulary Postural hypotension in adults: fludrocortisone
FLUNARIZINE 5mg capsules 20 Formulary NICE Unlicensed Evidence summary: Flunarizine for migraine prophylaxis
Fluocinolone intravitreal implant 11.04.01 Restricted Use NICE TA590: Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis
Fluocinolone intravitreal implant 11.04.01 Restricted Use NICE TA301: Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy
Fluoxetine 04.03.03 Formulary NICE evidence summary: Fluoxetine for hypersexuality
Fluticasone furoate & vilanterol 03.02 Formulary NICE New Medicine Evidence Summary 34: Fluticasone furoate & vilanterol inhaler
Fluticasone furoate, umeclidinium & vilanterol inhaler 03.02 Formulary COPD: fluticasone furoate, umeclidinium and vilanterol (Trelegy)
Follitropin Alfa biosimilar 06.05.01 Restricted Use NICE KTT15: Biosimilar medicines
Formoterol fumarate, beclometasone dipropionate and glycopyrronium bromide 03.02 Formulary NICE Evidence Summary (ES17) June 2018
Fosfomycin 05.01.07 Formulary NICE Evidence summary: Fosfomycin for resistant urinary tract infections
Fulvestrant 08.03.04.01 Restricted Use NICE TA503: Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer
Fulvestrant 08.03.04.01 Restricted Use NICE TA239: Fulvestrant for the treatment of locally advanced or metastatic breast cancer
Gabapentin 04.07.03 Formulary CKS - Restless legs syndrome
Gefitinib 08.01.05 Restricted Use NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer
Gefitinib 08.01.05 Restricted Use NICE TA192: Lung cancer (non-small-cell, first line) - gefitinib
Gemcitabine 08.01.03 Formulary NICE TA85: Pancreatic cancer - gemcitabine
Gemcitabine 08.01.03 Formulary NICE TA116: Breast cancer - gemcitabine
Gemcitabine 08.01.03 Formulary NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Gemtuzumab ozogamicin 08.01.05 Restricted Use NICE TA545: Gemtuzumab ozogamicin for untreated acute myeloid leukaemia
Glatiramer Acetate 08.02.04 Formulary Glatiramer for the treatment of MS
Glecaprevir/Pibrentasvir 05.03.03.02 Formulary NICE TA499: Glecaprevir–pibrentasvir for treating chronic hepatitis C
GLIADEL wafer Carmustine 7.6mg 20 Formulary NICE TA121: Glioma - carmustine implants and temozolomide
GLYCERYL TRINITRATE Ointment 0.2% 20 Non Formulary NICE Evidence summary: 0.2% glyceryl trinitrate ointment for chronic anal fissures
Glycopyrrolate/ indacaterol inhaler 03.01.04 Non Formulary NICE New Medicine Evidence Summary 33: indacaterol/glycopyrronium (Ultibro Breezhaler)
Glycopyrronium 01.02 Formulary NICE evidence summary: Glycopyrronium for hypersalivation
Glycopyrronium tablets 20 Non Formulary NICE Evidence Summary: glycopyrronium for hyperhidrosis
Golimumab 10.01.03 Restricted Use NICE TA220: psoriatic arthritis
Golimumab 10.01.03 Restricted Use NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Golimumab 10.01.03 Restricted Use NICE TA497: Golimumab for treating non-radiographic axial spondyloarthritis
Golimumab 10.01.03 Restricted Use NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Golimumab 10.01.03 Non Formulary NICE TA497: Golimumab for treating non-radiographic axial spondyloarthritis
Golimumab 01.05.03 Restricted Use NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis
Guanfacine 04.04 Formulary NICE ESNM70: Attention deficit hyperactivity disorder in children and young people
Guselkumab 13.05.03 Restricted Use NICE TA521: Treatment in moderate to severe plaque psoriasis
Haloperidol 04.02.01 Formulary COVID19: NICE (NG163) Managing symptoms (incl EOL) in the community
Hyoscine Butylbromide 01.02 Formulary COVID19: NICE (NG163) Managing symptoms (incl EOL) in the community
Ibrutinib 08.01.05 Restricted Use NICE TA491: Ibrutinib for treating Waldenstrom’s macroglobulinaemia
Ibrutinib 08.01.05 Restricted Use NICE TA429: Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation
Ibrutinib 08.01.05 Restricted Use NICE TA502: Ibrutinib for treating relapsed or refractory mantle cell lymphoma
Idelalisib 08.01.05 Restricted Use NICE TA604: Idelalisib for treating refractory follicular lymphoma (not recommended)
Idelalisib 08.01.05 Restricted Use NICA TA359: Chronic lymphocytic leukaemia - Idelalisib
Imatinib 08.01.05 Restricted Use NICE TA425:Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Imatinib 08.01.05 Restricted Use NICE TA426:Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
Infliximab 01.05.03 Restricted Use NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis
Infliximab 01.05.03 Restricted Use NICE TA163: Ulcerative colitis (acute manifestations) Infliximab
Infliximab 01.05.03 Restricted Use NICE TA187: Crohns disease - infliximab & adalimumab
Infliximab 13.05.03 Formulary NICE TA134: Infliximab for psoriasis
Infliximab 10.01.03 Restricted Use NICE TA195: Rheumatoid arthritis (after failure of a TNF inhibitor)
Infliximab 10.01.03 Restricted Use NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Infliximab 10.01.03 Restricted Use NICE TA199: Psoriatic arthritis
Infliximab 10.01.03 Restricted Use NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Infliximab 01.05.03 Restricted Use NICE TA163: Ulcerative colitis (acute manifestations) Infliximab
Infliximab 01.05.03 Restricted Use NICE KTT15: Biosimilar medicines
Infliximab 01.05.03 Restricted Use NICE TA187: Crohns disease - infliximab & adalimumab
Infliximab 01.05.03 Restricted Use NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis
Inotuzumab Ozogamicin 08.01.05 Restricted Use NICE TA541: Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia
Insulin Glargine biosimilar 06.01.01.02 Formulary NICE KTT15: Biosimilar medicines
Interferon Alfa-2b 08.02.04 Non Formulary NICE TA75: Interferon Alfa - Chronic Hepatitis C
Interferon Beta-1a 08.02.04 Restricted Use NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis
Interferon Beta-1a 08.02.04 Restricted Use NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis
Interferon beta-1b 08.02.04 Restricted Use NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis
Iodozyme® A5.03.02 Non Formulary NICE Medtech innovation briefing on Oxyzyme and Iodozyme
Ipilimumab 08.01.05 Restricted Use NICE TA268: Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma
Ipilimumab 08.01.05 Restricted Use NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma
Ipilimumab 08.01.05 Restricted Use NICE TA319: Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma
Ivabradine 02.06.03 Restricted Use NICE Guidance on Stable Angina (2011)
Ivermectin 13.10.04 Restricted Use NICE Evidence summary: Ivermectin for difficult-to-treat scabies
Ivermectin cream 13.06 Formulary NICE new medicine summary: Inflammatory lesions of papulopustular rosacea
Ixazomib 08.01.05 Restricted Use NICE: Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (TA505)
Ixekizumab 13.05.02 Restricted Use NICE TA537: Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs
Ketamine oral solution 04.07.03 Formulary NICE Unlicensed medicine review 27: Ketamine for chronic pain
Lamivudine 05.03.01 Restricted Use CG165: Chronic Hepatitis B
Lanadelumab 03.04.03 Restricted Use NICE TA605: Lanadelumab for preventing recurrent attacks of hereditary angioedema
Lapatinib 08.01.05 Restricted Use NICE TA257: Lapatinib in HER-2 positive metastatic breast cancer
Ledipasvir and Sofosbuvir 05.03.03.02 Restricted Use NICE TAG363: Ledipasvir–sofosbuvir for treating chronic hepatitis C
Lenalidomide 08.02.04 Restricted Use NICE: Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (TA505)
Lenvatinib 08.01.05 Restricted Use NICE TA535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine
Lenvatinib 08.01.05 Restricted Use NICE TA551: Lenvatinib for untreated advanced hepatocellular carcinoma
Lenvatinib 08.01.05 Restricted Use NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma
Lesinurad 10.01.04 Non Formulary NICE: Lesinurad for treating chronic hyperuricaemia in people with gout (TA506)
Lesinurad & Allopurinol 10.01.04 Non Formulary NICE: Lesinurad for treating chronic hyperuricaemia in people with gout (TA506)
Levomepromazine 04.06 Restricted Use COVID19: NICE (NG163) Managing symptoms (incl EOL) in the community
Liposomal Cytarabine-Daunorubicin 08.01.02 Restricted Use NICE TA552: Liposomal cytarabine–daunorubicin for untreated acute myeloid leukaemia
Lorazepam 04.01.02 Formulary COVID19: NICE (NG163) Managing symptoms (incl EOL) in the community
Lorlatinib 08.01.05 Restricted Use NICE TA628: Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer
Lubiprostone 01.06.07 Non Formulary NICE TA318: Lubiprostone for treating chronic idiopathic constipation
Lumacaftor + Ivacaftor 03.07 Restricted Use NICE TA398: Lumacaftor–ivacaftor for treating cystic fibrosis homozygous for the F508del mutation
Lusutrombopag 09.01.04 Restricted Use NICE TA617: Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure
Magnesium Glycerophosphate 09.05.01.03 Formulary NICE: Evidence Summary: Magnesium glycerophosphate
Mannitol inhalation 03.07 Restricted Use NICE: Cystic fibrosis - mannitol dry powder for inhalation (TA266)
Melatonin 04.01.01 Non Formulary NICE KTT6: Hypnotics
Melatonin 04.01.01 Restricted Use NICE Evidence summary: Melatonin for sleep disorders in children with ADHD
Melatonin 04.01.01 Restricted Use NICE guideline [NG11]:Challenging behaviour and learning disabilities
Mepilex Border A5.02.03 Non Formulary NICE: Mepilex Border Heel & Sacrum for preventing pressure ulcers
Mepolizumab 03.04.02 Formulary NICE TA431: Mepolizumab for treating severe refractory eosinophilic asthma
Metformin 06.01.02.02 Formulary NICE Evidence summary: Metformin for PCOS in women who are not planning pregnancy
Midazolam 15.01.04.01 Formulary COVID19: NICE (NG163) Managing symptoms (incl EOL) in the community
Midodrine 02.07.02 Formulary NICE: Orthostatic hypotension: midodrine (ESNM61)
Midostaurin 08.01.05 Restricted Use NICE TA523 - untreated acute myeloid leukaemia
Mifamurtide 08.02.04 Restricted Use NICE TA235: Osteosarcoma - mifamurtide: guidance
Mifepristone 07.01.02 Formulary NICE Evidence summary: Mifepristone for induction of labour in late intrauterine fetal death
Migalastat 09.08.01 Non Formulary NICE HST4: Migalastat for treating Fabry disease
Minocycline 05.01.03 Non Formulary NICE therapeutic topic: Minocycline
Mirabegron 07.04.02 Formulary NICE: TA290 - Mirabegron for overactive bladder
Modafinil 04.04 Restricted Use NICE Evidence Summary: Modafinil for fatigue in multiple sclerosis
Modafinil 04.04 Restricted Use NICE Evidence Summary: Modafinil for excessive daytime sleepiness in Parkinson’s disease
Morphine 04.07.02 Formulary COVID19: NICE (NG163) Managing symptoms (incl EOL) in the community
Mycophenolate Mofetil 08.02.01 Restricted Use NICE Evidence summary: Mycophenolate for scleroderma
Mycophenolate Mofetil 08.02.01 Restricted Use NICE Evidence summary: Mycophenolate for SLE
Mycophenolic acid (sodium) 08.02.01 Formulary NICE Evidence summary: Mycophenolate for scleroderma
Naftidrofuryl 02.06.04 Formulary NICE TA223: Intermittent claudication drugs
Naftidrofuryl 02.06.04 Formulary NICE CG147: Lower limb peripheral arterial disease management
Naltrexone 04.10.03 Formulary NICE TA115: Drug misuse - naltrexone
Natalizumab 08.02.04 Formulary NICE TA127: Multiple sclerosis - natalizumab
Necitumumab 08.01.05 Non Formulary NICE TA411: Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer
Neratinib 08.03.04.01 Restricted Use NICE TA 612: Neratinib for extended adjuvant treatment of hormone receptor-positive, HER2-positive early stage breast cancer after adjuvant trastuzumab
Netupitant and Palonosetron 04.06 Restricted Use NICE ESNM69: Prevention of chemotherapy induced nausea and vomiting in adults
Nilotinib 08.01.05 Restricted Use NICE TA426: Dasatinib, nilotinib and imatinib for first line treatment of CML
Nilotinib 08.01.05 Restricted Use NICE TA426:Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
Nilotinib 08.01.05 Restricted Use NICE TA425:Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Nilotinib 08.01.05 Restricted Use NICE TA425: Dasatinib, nilotinib and high dose imatinib for CML
Nintedanib 03.11 Restricted Use NICE TA379:Nintedanib for treating idiopathic pulmonary fibrosis
Nintedanib 03.11 Restricted Use NICE TA347: Recurrent non-small-cell lung cancer
Niraparib 08.02.04 Restricted Use NICE TA528: Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer
Nivolumab 08.02.04 Restricted Use NICE TA581: Nivolumab with ipilimumab for untreated advanced renal cell carcinoma
Nivolumab 08.02.04 Restricted Use NICE TA417: Nivolumab for previously treated advanced renal cell carcinoma
Nivolumab 08.02.04 Restricted Use NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma
Nivolumab 08.02.04 Restricted Use NICE TA483: Nivolumab for previously treated squamous non-small-cell lung cancer
Nivolumab 08.02.04 Restricted Use NICE TA484: Nivolumab for previously treated non-squamous non-small-cell lung cancer
Nivolumab 08.02.04 Restricted Use NICE TA490:Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy
Nivolumab 08.02.04 Restricted Use NICE TA384: Nivolumab for treating advanced (unresectable or metastatic) melanoma
Nivolumab 08.02.04 Restricted Use NICE TA462:Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma
Nivolumab 08.02.04 Restricted Use NICE TA530: Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy (not recommended)
Obeticholic acid 01.09.01 Restricted Use NICE TA443: Obeticholic acid for treating primary biliary cholangitis
Obinutuzumab 08.02.03 Restricted Use NICE TA343: Obinutuzumab with chlorambucil for CLL
Obinutuzumab 08.02.03 Restricted Use NICE TA472: Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab
Obinutuzumab 08.02.03 Restricted Use NICE TA513: Obinutuzumab for untreated advanced follicular lymphoma
Ocrelizumab 08.02.03 Restricted Use NICE TA585: Ocrelizumab for treating primary progressive multiple sclerosis
Ocrelizumab 08.02.03 Restricted Use NICE TA533: Ocrelizumab for treating relapsing–remitting multiple sclerosis
Ofatumumab 08.02.03 Non Formulary NICE TA344: Ofatumumab with chlorambucil or bendamustine for CLL
Olaparib 08.02.04 Restricted Use NICE TA620: Olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer
Olaparib 08.02.04 Restricted Use NICE TA598: Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy
Omalizumab 03.04.02 Restricted Use NICE TA278: Omalizumab for treating allergic asthma
Omalizumab 03.04.02 Restricted Use NICE TA339: Omalizumab for previously treated chronic spontaneous urticaria
Ombitasvir/ paritaprevir/ ritonavir 05.03.03.02 Restricted Use NICE TAG365: Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C
Omega-3-Acid Ethyl Esters 02.12 Non Formulary NICE: schizophrenia - omega-3 fatty acid medicines
Omega-3-Marine Triglycerides 02.12 Non Formulary NICE: schizophrenia - omega-3 fatty acid medicines
Ondansetron 04.06 Formulary Ondansetron for vomiting in children with gastroenteritis- NICE evidence summary
Orlistat 04.05.01 Formulary NICE CG189: Obesity: identification, assessment and management
Osimertinib 08.01.05 Restricted Use NICE TA416: Osimertinib in non-small-cell lung cancer
Oxaliplatin 08.01.05 Formulary NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin
Oxyzyme® A5.03.02 Non Formulary NICE Medtech innovation briefing on Oxyzyme and Iodozyme
Paclitaxel 08.01.05 Formulary NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Paclitaxel 08.01.05 Formulary NICE TA101: Prostate cancer (hormone-refractory) - docetaxel
Paclitaxel - Albumin Bound Formulation 08.01.05 Restricted Use NICE TA476: Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer
Padeliporfin dipotassium 08.03.04.02 Non Formulary NICE TA546: Padeliporfin not recommended for untreated localised prostate cancer
Palbociclib 08.03.04.01 Formulary NICE TA495: Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
Palbociclib 08.03.04.01 Formulary NICE TA619: Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer
Panitumumab 08.01.05 Restricted Use NICE TA439: Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
Panobinostat 08.01.05 Formulary NICE TA380: Panobinostat for treating multiple myeloma after at least 2 previous treatments
Patiromer calcium 09.02.01.01 Formulary NICE TA623: Patiromer for treating hyperkalaemia
Pazopanib 08.01.05 Restricted Use NICE TA 215: Pazopanib in renal cell cancer
Pegaptanib Sodium 11.08.02 Non Formulary NICE guidance on pegaptanib in AMD (August 2008)
Pegaspargase 08.01 Formulary NICE TA408: Pegaspargase for treating acute lymphoblastic leukaemia
Peginterferon Alfa-2a 08.02.04 Formulary NICE TA106: Hepatitis C - peginterferon alfa & ribavirin
Peginterferon Alfa-2a 08.02.04 Formulary NICE TA75: Hepatitis C - pegylated interferons, ribavirin & alfa interferon
Peginterferon Alfa-2a 08.02.04 Formulary NICE TA 200: Hepatitis C - peginterferon alfa & ribavirin
Peginterferon Alfa-2a 08.02.04 Formulary NICE TA 96: Hepatitis B - peginterferon alfa
Peginterferon Alfa-2a 08.02.04 Formulary NICE TA 300: Hepatitis C - peginterferon alfa
Pegloticase 20 Non Formulary NICE: TA291 - Pegloticase not recommended for severe chronic gout
Pembrolizumab 08.01.05 Restricted Use NICE TA600: Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer
Pembrolizumab 08.01.05 Restricted Use NICE TA366: Pembrolizumab for advanced melanoma not previously treated with ipilimumab
Pembrolizumab 08.01.05 Restricted Use NICE TA428: Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy
Pembrolizumab 08.01.05 Restricted Use NICE TA531: Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer
Pembrolizumab 08.01.05 Restricted Use NICE TA357: Pembrolizumab for melanoma after ipilimumab
Pembrolizumab 08.01.05 Restricted Use NICE TA522: Pembrolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable
Pemetrexed 08.01.03 Restricted Use NICE TA402:Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin
Pemetrexed 08.01.03 Restricted Use NICE TA190: Lung cancer (non-small-cell) - pemetrexed (maintenance)
Pemetrexed 08.01.03 Restricted Use NICE TA181: Lung cancer (non-small cell, first line treatment) - pemetrexed
Pemetrexed 08.01.03 Restricted Use NICE TA135: Mesothelioma - pemetrexed disodium
PENTOSAN POLYSULPHATE 07.04.03 Formulary Pentosan NICE TA 610
Perampanel 04.08.01 Formulary NICE CG137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care
Perampanel 04.08.01 Formulary NICE evidence summary
Peristeen transanal irrigation system 16.01 Non Formulary NICE Peristeen transanal irrigation system
Pertuzumab 08.01.05 Restricted Use NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer
Pertuzumab 08.01.05 Restricted Use NICE TA424: Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer
Pimecrolimus 13.05.03 Formulary NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema)
Pirfenidone 03.11 Restricted Use NICE: Idiopathic pulmonary fibrosis - pirfenidone (TA504)
Pixantrone 08.01.02 Restricted Use TA306:Pixantrone monotherapy
Pomalidomide 08.02.04 Restricted Use NICE TA427: Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib
Ponatinib 08.01.05 Restricted Use NICE TA451: Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia
Pramipexole 04.09.01 Formulary NICE CKS: Restless legs syndrome guidance
Prasugrel 02.09 Restricted Use NICE TA317 (replaces TA182): Acute coronary syndrome - prasugrel
Pregabalin 04.07.03 Formulary CKS - Restless legs syndrome
Promethazine 03.04.01 Formulary NICE Evidence summary: Promethazine for rapid tranquillisation in mental health settings
Prucalopride 01.06.07 Restricted Use TA211 - Constipation (women) - prucalopride
Quetiapine 04.02.01 Formulary NICE Evidence summary: Quetiapine for generalised anxiety disorder
Radium-223 dichloride 08.03.04.02 Restricted Use NICE TA412: Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases
Raloxifene Hydrochloride 06.04.01.01 Formulary NICE quick reference guide on osteoporosis
Raloxifene Hydrochloride 06.04.01.01 Formulary NICE: Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (TA161)
Raloxifene Hydrochloride 06.04.01.01 Formulary NICE: Raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women (TA160)
Ramipril 02.05.05.01 Formulary NICE evidence summary: ramipril for peripheral arterial disease
Ramucirumab 08.01.05 Non Formulary NICE TA403:Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer
Ranolazine 02.06.03 Restricted Use NICE Guidance on Stable Angina (2011)
ReCell Spray on Skin system A5.04 Non Formulary NICE MTG21: ReCell Spray‑On Skin system for burn injury
Regorafenib 08.01.05 Restricted Use NICE TA488:Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours
Regorafenib 08.01.05 Restricted Use NICE TA555: Regorafenib for previously treated advanced hepatocellular carcinoma
Reslizumab 03.04.02 Restricted Use NICE TA479: Reslizumab for treating severe eosinophilic asthma
Retigabine 04.08.01 Non Formulary NICE TA232: Retigabine for the adjunctive treatment of adults with partial onset seizures in epilepsy with and without secondary generalisation
Ribavirin 05.03.05 Restricted Use NICE TA75: Hepatitis C - pegylated interferons, ribavirin and alfa interferon
Ribavirin 05.03.05 Restricted Use NICE TA106: Hepatitis C - peginterferon alfa and ribavirin
Ribavirin 05.03.05 Restricted Use NICE TA200: Hepatitis C - peginterferon alfa and ribavirin
Ribociclib 08.03.04.01 Restricted Use NICE TA496: Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
Ribociclib 08.03.04.01 Restricted Use NICE TA593: Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer
Rifaximin 05.01.07 Formulary NICE evidence summary: Rifaximin for pouchitis
Riluzole 04.09.03 Restricted Use NICE TA20: Motor neurone disease - riluzole
Rituximab 08.02.03 Restricted Use NICE guidelines for rituximab
Rituximab 10.01.03 Restricted Use NICE TA195: Rheumatoid arthritis - after failure of a TNF inhibitor
Rituximab 08.02.03 Restricted Use Rituximab for ITP-NICE evidence summary
Rituximab 08.02.03 Restricted Use NICE guidelines for rituximab
Rituximab 10.01.03 Restricted Use NICE TA195: Rheumatoid arthritis - after failure of a TNF inhibitor
Romiplostim 09.01.04 Restricted Use NICE TA221: Thrombocytopenic purpura - romiplostim
Ropinirole 04.09.01 Formulary NICE CKS: Restless legs syndrome guidance
Rucaparib 08.02.04 Restricted Use NICE TA611: Rucaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer
Ruxolitinib 08.01.05 Restricted Use NICE TA386: Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis
Sacubitril valsartan 02.05.05.02 Formulary NICE TA388: Sacubitril valsartan for heart failure
Sarilumab 10.01.03 Restricted Use NICE TA485:Sarilumab for moderate to severe rheumatoid arthritis
Secukinumab 13.05.03 Restricted Use NICE TA445: Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs
Secukinumab 13.05.03 Restricted Use NICE TA407: Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors
Secukinumab 13.05.03 Restricted Use NICE TA350: Plaque Psoriasis
Sildenafil 02.05.01 Formulary NICE Evidence summary: Sildenafil for digital ulcers
Sildenafil 02.05.01 Formulary NICE ESUOM51: Pulmonary hypertension in neonates
Simeprevir 05.03.03.02 Non Formulary NICE TA331: Simeprevir with peginterferon alfa & ribavirin for hepatitis C
Sipuleucel- T 20 Non Formulary NICE TA322: Sipuleucel-T for prostate cancer
Sodium Valproate 04.02 Non Formulary NICE evidence summary: valproate for behavioural disturbances in dementia
Sodium Valproate 04.08.01 Formulary NICE 2019: Valproate: Summary of NICE guidance and safety advice
Sodium valproate 04.02.03 Formulary NICE 2019: Valproate: Summary of NICE guidance and safety advice
Sodium zirconium cyclosilicate 09.02.01.01 Formulary NICE TA599: Sodium zirconium cyclosilicate for treating hyperkalaemia
Sofosbuvir 05.03.03.02 Restricted Use NICE TA330: Sofosbuvir for treating chronic hepatitis C
Sofosbuvir and Velpatasvir 05.03.03.02 Restricted Use NICE TA430: Sofosbuvir–velpatasvir for treating chronic hepatitis C
Sofosbuvir, Velpatasvir and Voxilaprevir 05.03.03.02 Restricted Use NICE TA507: Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C
Somatropin 06.05.01 Restricted Use NICE KTT15: Biosimilar medicines
Somatropin 06.05.01 Restricted Use NICE TA64: Growth hormone deficiency (adults)
Somatropin 06.05.01 Restricted Use NICE TA188: Somatropin for growth failure in children
Sorafenib 08.01.05 Restricted Use NICE TA474: Sorafenib for treating advanced hepatocellular carcinoma
Sorafenib 08.01.05 Restricted Use NICE TA535: Sorafenib for treating differentiated thyroid cancer after radioactive iodine.
Sunitinib 08.01.05 Restricted Use NICE TA449:Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
Sunitinib 08.01.05 Restricted Use NICE TA179: Gastrointestinal stromal tumours - sunitinib
Sunitinib 08.01.05 Restricted Use NICE TA169: Renal cell carcinoma - sunitinib
Tacrolimus 13.05.03 Formulary NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema)
Tadalafil 07.04.05 Formulary NICE: Hyperplasia (benign prostatic) - tadalafil (terminated appraisal) (TA273)
Talimogene laherparepvac 08.02.04 Restricted Use NICE TA410: Talimogene laherparepvec for treating unresectable metastatic melanoma
Tegafur with Uracil 08.01.03 Formulary NICE TA61: Capcitabine and tegafur - Colorectal cancer
Telaprevir 05.03.03.02 Non Formulary NICE TA252: Telaprevir in hepatitis C
Temozolomide 08.01.05 Formulary NICE TA23: Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer)
Temozolomide 08.01.05 Formulary NICE TA121: Glioma (newly diagnosed and high grade)
Tenofovir Disproxil 05.03.01 Restricted Use NICE TA173: Hepatitis B (chronic) - tenofovir disoproxil
Teriflunomide 08.02.04 Restricted Use NICE TA 303: Teriflunomide for relapsing remitting MS
Teriparatide 06.06.01 Restricted Use NICE: Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (TA161)
Teriparatide 06.06.01 Restricted Use NICE: Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women (TA161)
Thiamine 09.06.02 Formulary NICE: Management of alcohol-related physical complications
Thiamine 09.06.02 Formulary NICE: Alcohol dependence - diagnosis, assessment and management
Thiamine 09.06.02 Formulary NICE: Alcohol dependence - diagnosis, assessment and management
Thiamine 09.06.02 Formulary NICE: Management of alcohol-related physical complications
Ticagrelor 02.09 Restricted Use NICE TAG 236: Ticagrelor for ACS
Ticagrelor 02.09 Restricted Use NICE TA420: Ticagrelor for preventing atherothrombotic events after myocardial infarction
Tildrakizumab 13.05.03 Restricted Use NICE TA575: Tildrakizumab for treating moderate to severe plaque psoriasis
Tisagenlecleucel 08.02.04 Formulary NICE TA567: Tisagenlecleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies
Tisagenlecleucel 08.02.04 Formulary NICE TA554:Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years
Tivozanib 08.01 Restricted Use NICE TA512: Tivozanib for treating advanced renal cell carcinoma
Tobramycin inhaler 05.01.04 Restricted Use NICE: Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin (TA276)
Tocilizumab 10.01.03 Restricted Use NICE TA247:Tocilizumab in RA
Tocilizumab 10.01.03 Restricted Use NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
Tocilizumab 10.01.03 Restricted Use NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Tocilizumab 10.01.03 Restricted Use NICE TA518: Tocilizumab for treating giant cell arteritis
Tofacitinib citrate 10.01.03 Restricted Use NICE TA480: Tofacitinib for moderate to severe rheumatoid arthritis
Tofacitinib citrate 10.01.03 Restricted Use NICE TA543:Tofacitinib for treating active psoriatic arthritis
Tofacitinib citrate 10.01.03 Restricted Use NICE TA547: Tofacitinib for moderately to severely active ulcerative colitis
Tolvaptan 06.05.02 Restricted Use NICA TA358: Autosomal dominant polycystic kidney disease - tolvaptan
Tolvaptan 06.05.02 Non Formulary NICA TA358: Autosomal dominant polycystic kidney disease - tolvaptan
Topotecan 08.01.05 Formulary NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Topotecan 08.01.05 Formulary NICE TA183: Cervical cancer (recurrent) - topotecan
Topotecan 08.01.05 Formulary NICE TA184: Lung cancer (small-cell) - topotecan
Trabectedin 08.01.05 Restricted Use NICE TA185: Soft tissue sarcoma - trabectedin
Trabectedin 08.01.05 Restricted Use NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Trametinib 08.01.05 Restricted Use NICE TA396: Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
Trametinib 08.01.05 Restricted Use NICE TA544: Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma
Tranexamic Acid 02.11 Formulary NICE Evidence summary: Tranexamic acid for significant haemorrhage following trauma
Tranexamic Acid 02.11 Formulary NICE guideline on heavy menstrual bleeding
Trastuzumab 08.01.05 Formulary NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer
Trastuzumab 08.01.05 Formulary NICE TA34: Breast cancer - trastuzumab
Trastuzumab 08.01.05 Formulary NICE TA208: Gastric cancer (HER2-positive metastatic) - trastuzumab
Trastuzumab 08.01.05 Formulary NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer
Trastuzumab 08.01.05 Restricted Use NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer
Trastuzumab 08.01.05 Restricted Use NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer
Trastuzumab 08.01.05 Restricted Use NICE TA208: Gastric cancer (HER2-positive metastatic) - trastuzumab
Trastuzumab 08.01.05 Restricted Use NICE TA34: Breast cancer - trastuzumab
Trastuzumab 08.01.05 Restricted Use NICE TA34: Breast cancer - trastuzumab
Trastuzumab 08.01.05 Restricted Use NICE TA208: Gastric cancer (HER2-positive metastatic) - trastuzumab
Trastuzumab 08.01.05 Restricted Use NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer
Trastuzumab 08.01.05 Restricted Use NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer
Trastuzumab emtansine 08.01.05 Restricted Use NICE TA458:Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane
Ulipristal 06.07.02 Non Formulary NICE guidelines on heavy menstrual bleeding
UroLift system 20 Non Formulary NICE MTG26: UroLift for treating symptoms of BPH
Ustekinumab 13.05.03 Formulary NICE TA180: Psoriasis - ustekinumab
Ustekinumab 13.05.03 Formulary NICE TA340: Ustekinumab for treating active psoriatic arthritis
Ustekinumab 13.05.03 Formulary NICE TA455:Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
Ustekinumab 13.05.03 Formulary NICE TA456:Ustekinumab for moderately to severely active Crohn’s disease after previous treatment
Valproate semisodium 04.02.03 Formulary NICE 2019: Valproate: summary of NICE guidance and safety advice
Varenicline 04.10.02 Formulary NICE TA123: Varenicline
Vedolizumab 01.05.03 Restricted Use NICE TA352: Vedolizumab for Crohn’s disease
Vedolizumab 01.05.03 Restricted Use NICE TA342: Vedolizumab for ulcerative colitis
Vemurafenib 08.01.05 Restricted Use NICE TA269: Vemurafenib for treating malignant melanoma
Venetoclax 08.01.05 Restricted Use NICE TA561: Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia
Venetoclax 08.01.05 Restricted Use NICE TA487: Venetoclax for treating chronic lymphocytic leukaemia
Verteporfin 11.08.02 Restricted Use NICE Guidance 82: Age-related macular degeneration
Vinflunine 08.01.04 Restricted Use NICE: Urothelial tract carcinoma (transitional cell, advanced, metastatic) - vinflunine (TA272)
Vismodegib 08.01.05 Restricted Use NICE TA489: Vismodegib for treating basal cell carcinoma
Vortioxetine 04.03.03 Formulary NICE TA 367 - Vortioxetine for treating major depressive episodes
Zoledronic Acid 06.06.02 Formulary NICE NG101: Early and locally advanced breast cancer: diagnosis and management
Zolpidem 04.01.01 Formulary NICE TAG 77: Zaleplon, zolpidem and zopiclone for the management of insomnia
Zopiclone 04.01.01 Formulary NICE TAG 77: Zaleplon, zolpidem and zopiclone for the management of insomnia
Nottinghamshire Area Prescribing Committee